
CLAIMS

1. A stabilized pharmaceutical composition comprising a nonpeptidic pharmaceutically active ingredient ~~having a primary or secondary amino group,~~selected from the group consisting of:
compound A (1-[5-(2-fluorophenyl)-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof, compound B (n-methyl-1-[5-(2-methylphenyl)-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine) or a salt thereof, and compound C (1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine] or a salt thereof, an excipient and ~~an acidic compound~~fumaric acid as a stabilizer~~, wherein the nonpeptidic pharmaceutically active ingredient is a compound represented by the formula~~



~~wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocylic group, R^2, R^3 and R^4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R^5 is a hydrogen atom or an optionally substituted hydrocarbon group,~~
~~or a salt thereof~~.

~~2. The pharmaceutical composition of claim 1, wherein the acidic compound is an organic acid or a salt thereof.~~

~~3~~2. The pharmaceutical composition of claim ~~2~~1, wherein the nonpeptidic pharmaceutically active ingredient has a pKa value

higher than that of the ~~organic~~ fumaric acid or a salt thereof.

~~4~~3. The pharmaceutical composition of claim 1, wherein the nonpeptidic pharmaceutically active ingredient is an organic acid salt.

~~5~~4. The pharmaceutical composition of claim 1, wherein the excipient has pH 4.5 or above when dissolved or dispersed in water.

~~6~~5. The pharmaceutical composition of claim 1, wherein the excipient is any one kind or more selected from the group consisting of mannitol, croscarmellose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyethylene glycol, polyvinylpyrrolidone, crystalline cellulose, lactose, sucrose, starch, cornstarch, titanium oxide (TiO2) and light anhydrous silicic acid.

~~7~~6. The pharmaceutical composition of claim 1, wherein the nonpeptidic pharmaceutically active ingredient is a salt with an unsaturated carboxylic acid.

~~8. The pharmaceutical composition of claim 2, wherein the organic acid is any one kind or more selected from the group consisting of adipic acid, ascorbic acid, benzoic acid, oleic acid, succinic acid, acetic acid, tartaric acid, sorbic acid, fumaric acid, lactic acid, maleic acid, malonic acid, citric acid and malic acid.~~

~~9. The pharmaceutical composition of claim 1, wherein the nonpeptidic pharmaceutically active ingredient is 1-[5-(2-fluorophenyl)-1-[(6-methylpyridin-3-yl) sulfonyl]-1H-pyrrol-3-yl)-N-methylmethanamine or a salt thereof, 1-[4-fluoro-5-phenyl-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof, N-methyl-1-[5-(4-methyl-3-thienyl)-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine or a salt thereof, 1-[5-(2-fluorophenyl)-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof, N-methyl-1-[5-(2-methylphenyl)-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine or a salt thereof, or 1-[4-fluoropyridin-3-yl)-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof.~~

~~10~~7. The pharmaceutical composition of claim 1, which is a solid preparation.

~~11~~8. A method of stabilizing a pharmaceutical composition comprising a nonpeptidic pharmaceutically active ingredient ~~having a primary or secondary amino group~~ selected from the group consisting of:
compound A (1-[5-(2-fluorophenyl)-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof, compound B (n-methyl-1-[5-(2-methylphenyl)-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]methanamine) or a salt thereof, and compound C (1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine] or a salt thereof, and an excipient, comprising adding ~~an acidic compound~~fumaric acid to the pharmaceutical composition.